GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CJC-1134-PC

Company
ConjuChem
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00638716

    A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy

    Not yet reported ConjuChem 122 participants Est. completion 2008-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00674466

    A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

    Not yet reported ConjuChem 90 participants Est. completion 2008-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01514149

    Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

    Not yet reported ConjuChem 73 participants Est. completion 2013-03 22 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07057271

    A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

    Not yet reported Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. 464 participants Est. completion 2023-02-21 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07058545

    A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

    Not yet reported Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. 474 participants Est. completion 2023-02-20 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.